2024 ICD-10-CM Diagnosis Code P91.819

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

• Axonal neuropathy
• CNTNAP2-related developmental and epileptic encephalopathy
• Coenzyme Q10 deficiency
• Congenital axonal neuropathy with encephalopathy
• Encephalopathy due to COVID-19
• Encephalopathy, intracerebral calcification, retinal degeneration syndrome
• Epileptic encephalopathy with global cerebral demyelination
• Hypertrophic mitochondrial cardiomyopathy
• Lethal neonatal spasticity, epileptic encephalopathy syndrome
• Myoclonic epilepsy in non-progressive encephalopathy
• Neonatal encephalomyopathy, cardiomyopathy, respiratory distress syndrome
• Neonatal encephalopathy
• Neonatal encephalopathy
• SCN2A encephalopathy
• SCN8A-related epilepsy with encephalopathy
• Severe neonatal onset encephalopathy with microcephaly

Clinical Information

• GAIA Level 1 Neonatal Encephalopathy|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Encephalopathy|Level 1 Neonatal Encephalopathy

  gaia level 1 neonatal encephalopathy is defined by three criteria: first, a newborn infant (1-28 days of life) born at or beyond 35 weeks of gestation; second, an abnormal level of alertness or seizures; third, difficulty with initiating and maintaining respiration; fourth, depression of muscle tone.

• GAIA Level 2 Neonatal Encephalopathy|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Encephalopathy|Level 2 Neonatal Encephalopathy

  gaia level 2 neonatal encephalopathy is defined by three criteria: first, a newborn infant (1 to 28 days of life) born at or beyond 35 weeks of gestation; second, an abnormal level of alertness or seizures; third, either difficulty with initiating and maintaining respiration or depression of muscle tone.

• GAIA Level 3 Neonatal Encephalopathy|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Neonatal Encephalopathy|Level 3 Neonatal Encephalopathy

  gaia level 3 neonatal encephalopathy is defined by three criteria: first, a newborn infant (1-28 days of life) born at or beyond 35 weeks of gestation; second, an abnormal level of alertness or seizures; third, none of the following: a) difficulty with initiating or maintaining respiration; b) depression of muscle tone.

• GAIA Neonatal Encephalopathy Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Neonatal Encephalopathy Level of Diagnostic Certainty

  a subset of terminology related to neonatal encephalopathy, developed by the global alignment of immunization safety assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.

• GAIA Neonatal Encephalopathy Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Neonatal Encephalopathy Level of Diagnostic Certainty|Neonatal Encephalopathy Level of Diagnostic Certainty

  a classification of maternal and fetal outcomes relating to neonatal encephalopathy, developed by the global alignment of immunization safety assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.

• Neonatal Encephalopathy

  abnormal functioning of the central nervous system in the newborn period that may be due to a variety of etiologies including hypoxia/ischemia, metabolic disturbance, or infection.

• Severe Neonatal Encephalopathy Due to MECP2 Mutations

  an x-linked recessive condition caused by mutation(s) in the mecp2 gene, encoding methyl-cpg-binding protein 2. it is characterized by severe neonatal encephalopathy.

• Acute Motor and Sensory Axonal Neuropathy|Acute Motor And Sensory Axonal Neuropathy|Acute Motor-Sensory Axonal Neuropathy|Acute Motor-Sensory Axonal Neuropathy

  a subtype of guillain-barre syndrome that targets sensory motor axons, and is characterized by acute onset of quadriparesis, distal sensory loss, areflexia, and respiratory insufficiency.

• Acute Motor Axonal Neuropathy|AMAN

  a subtype of guillain-barre syndrome that targets motor axons, and is characterized by symmetric limb weakness, diffuse areflexia, facial and oropharyngeal muscle weakness, and respiratory insufficiency.

• Axonal Neuropathy

  any nerve disorder affecting the axon of a nerve.

• GAN wt Allele|GAN1|Giant Axonal Neuropathy (Gigaxonin) Gene|Gigaxonin wt Allele|KLHL16

  human gan wild-type allele is located in the vicinity of 16q24.1 and is approximately 65 kb in length. this allele, which encodes gigaxonin protein, is involved in both ubiquitination and neurofilament structure. mutation of the gene is associated with giant axonal neuropathy.

• Giant Axonal Neuropathy

  a rare inherited disorder affecting the neurofilaments. it is caused by mutations in the gan gene. it is characterized by the presence of abnormally large nerve cell axons. signs and symptoms include difficulty walking, sensory disturbances, lack of motor coordination and abnormal reflexes in the limbs.

• Spinocerebellar Ataxia, Autosomal Recessive, with Axonal Neuropathy 2|AOA2|Ataxia with Oculomotor Apraxia Type 2|SCAN2

  an autosomal recessive condition caused by mutation(s) in the setx gene, encoding probable helicase senataxin. it is characterized by juvenile onset progressive cerebellar ataxia, axonal sensorimotor peripheral neuropathy, and increased concentrations of serum alpha-fetoprotein. oculomotor apraxia is common, but is not always present.

• Coenzyme Q10 Deficiency

  a genetically heterogeneous condition, typically inherited in an autosomal recessive fashion, characterized by coenzyme q10 deficiency.

Present on Admission (POA)

P91.819 is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.

CMS POA Indicator Options and Definitions

Replacement Code

P91819 replaces the following previously assigned ICD-10-CM code(s):

• P91.8 - Other specified disturbances of cerebral status of newborn

Convert P91.819 to ICD-9-CM

• ICD-9-CM Code: 779.1 - NB cereb irrit NEC/NOS
  Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.

Code History

• FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
• FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
• FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
• FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
• FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
• FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
• FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018